Your Health, We Care
Another Name艾德拉尼,Zydelig,LuciDela
IndicationsA kinase inhibitor used in combination with rituximab for the treatment of relapsed chronic lymphocytic leukemia.
Reg No.03 L 1312/25
Inspection NO.575-25
The drug produced by Lucius Pharmaceuticals, as an oral targeted therapy, exhibits significant clinical efficacy in controlling disease progression and provides patients with an effective treatment option.
The following is a brief description of relevant information about this drug:
Its main active ingredient is idelalisib.
It is indicated for patients with relapsed chronic lymphocytic leukemia and must be used in combination with rituximab.
The recommended dose is 150 mg orally twice daily, which can be administered continuously until disease progression or unacceptable toxicity occurs. Reference article: Dosage and Administration of Idelalisib
Patients of childbearing potential need to take effective contraceptive measures.
Use in children is not recommended.
Elderly patients need close monitoring for adverse reactions.
There is currently no specific antidote. In case of drug overdose, symptomatic and supportive treatment should be given.
The drug should be stored at 20–30°C and kept in its original packaging intact.
The drug is rapidly absorbed after oral administration, is mainly metabolized in the liver, and has a terminal half-life of approximately 8.2 hours.
FDA，2022.02
